Secondhand Tobacco Smoke and Cardiovascular Disease
NCT04715568
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
This is a double-blind randomized placebo-controlled crossover clinical trial of efficacy and safety of an FDA-approved angiotensin receptor blocker (losartan) to improve cardiopulmonary outcomes in individuals with pre-Chronic Obstructive Pulmonary Disease (COPD) due to prolonged exposure to secondhand tobacco smoke.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Cardiovascular Diseases
- Hypertension
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 4
- Ages
- 40 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- University of California, San Francisco
- Last updated on ClinicalTrials.gov
- August 19, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- San Francisco Veterans' Affairs Medical Center · San Francisco, CA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.